Brain Derived Exosomes Are a Double-Edged Sword in Alzheimer’s Disease

Abstract

Brain derived exosomes (BDEs) are extracellular nanovesicles that are collectively released by all cell lineages of the central nervous system and contain cargo from their original cells. They are emerging as key mediators of communication and waste management among neurons, glial cells and connective tissue during both physiological and pathological conditions in the brain. We review the rapidly growing frontier of BDEs biology in recent years including the involvement of exosomes in neuronal development, maintenance and communication through their multiple signaling functions. Particularly, we highlight the important role of exosomes in Alzheimer’s disease (AD), both as a pathogenic agent and as a disease biomarker. Our understanding of such unique nanovesicles may offer not only answers about the (patho) physiological course in AD and associated neurodegenerative diseases but also ideal methods to develop these vesicles as vehicles for drug delivery or as tools to monitor brain diseases in a non-invasive manner because crossing the blood brain barrier is an inherent capability of exosomes. BDEs have potential as biomarkers and as therapeutic tools for AD and related brain disorders in the near future.

Introduction

Exosomes are small extracellular nano-sized vesicles between 30 and 150 nm in diameter (DeLeo and Ikezu, 2018) that were first described in the 1980s (Johnstone et al., 1987). They consist of one type of EVs and are categorized on the basis of their biogenesis pathways (Pan and Johnstone, 1983). Since then, exosomes have been isolated from nearly all mammalian cell types, including cells in the CNS such as neurons, astrocytes, oligodendrocytes, microglia, and Schwann cells, as well as endothelial cells (Faure et al., 2006; Sharma et al., 2013). Exosomes released from the nervous system are collectively called BDEs.

To form MVBs with ILVs, early endosomes undergo inward budding (Colombo et al., 2014). Then, ILVs are released into the extracellular environment as exosomes via fusion of MVBs with the plasma membrane (Heijnen et al., 1999; Mulcahy et al., 2014). Alternatively, exosomal formation can be regulated by sphingolipids, ceramides and tetraspanins (Trajkovic et al., 2008; Stuffers et al., 2009; van Niel et al., 2011). Otherwise, MVBs can fuse with the lysosomal membrane, resulting in degradation of ILVs and recycling of their content (Stuffers et al., 2009; Klumperman and Raposo, 2014). As a result of their origin and multifarious molecular cargo, including but not limited to gDNA, mRNA, other non-coding RNAs, lipids and proteins (Yokoi et al., 2019), the molecular species and relative amounts in exosomes are highly heterogeneous and complex in composition. Exosomes can randomly or selectively exhibit great variety depending on their membranes, cytosolic proteins, and nucleic acids compared with the cells that release them. Based on the proteomic and other comprehensive analyses, the heterogeneity of exosomes is conceptualized on the basis of their size, content (cargo), functional impact on recipient cells and cell of origin (source) (Kalluri and LeBleu, 2020). It is becoming increasingly clear that exosomes have specialized functions and play a key role in coagulation, intercellular signaling and waste management (van der Pol et al., 2012; Figure 1).

FIGURE 1

Colombo et al., 2014). Cargo sorting into exosomes involves the endosomal sorting complex required for transport (ESCRT)-dependent mechanism, which are managed by ESCRT proteins (ESCRT-0, I, II, and III) and their accessories (ALIX, TSG101, and VPS32) (Hurley, 2010; van Niel et al., 2018), and ESCRT-independent mechanism, which are mediated by neutral sphingomyelinase 2 (nSMaseII), tetraspanins, and the chaperone heat shock proteins (HSP70 and HSC70), can develop ILVs (Malla et al., 2018). ILVs have two fates, either fusing with the lysosome resulting in the degradation of the ILVs and their contents for recycling as an endolysosomal pathway (Klumperman and Raposo, 2014), or fusing with the plasma membrane where they are released into the extracellular space as exosomes through a secretory pathway (Heijnen et al., 1999). Microvesicles are formed directly by outward budding of the plasma membrane, a course which is managed by the ESCRT components and ADP ribosylation factor 6 (ARF6), some small GTPases, lipids, and Ca²⁺-dependent enzymatic machineries (Thompson et al., 2016). Apoptotic bodies are the largest of the EVs. They “bleb” off the cell membrane and contain material from cells undergoing apoptosis, which are typically engulfed by macrophages (Thompson et al., 2016). After release into the extracellular space, exosomes can be internalized by recipient cells mediated by the interaction of various exosomal surface proteins and cellular receptors via several mechanisms including phagocytosis, plasma membrane fusion, macropinocytosis and endocytosis (McKelvey et al., 2015). The contents of exosomes can effectively influence cellular processes through taking part in genetic/protein transfer, transcriptional regulation or post-transcriptional regulation. Alternatively, exosomes can be further fused with the lysosomes for degradation (Saeedi et al., 2019; You and Ikezu, 2019).

During the formation process, exosomes are comprised of enriched endosome-associated components such as flotillins and annexins (van Niel et al., 2006), ALIX, the ESCRT component, tumor susceptibility gene 101 protein (TSG101) (Lotvall et al., 2014) and lipid rafts, including cholesterol, sphingomyelin and ceramide (DeLeo and Ikezu, 2018). Moreover, membrane proteins, including tetraspanins such as abundant CD9, CD63, and CD81, that are considered as markers for exosomes and play important roles in the biogenesis of endosomes or MVBs (Lotvall et al., 2014; Kowal et al., 2016). Depending on the cell type from which they are secreted, exosome vesicles themselves also hold particular and varied types of markers that contribute to identifying their origins (Lotvall et al., 2014; Kowal et al., 2016). For example, neuronal L1 cell adhesion molecule (L1CAM) can be used as a biomarker for isolating BDEs (Cicognola et al., 2019).

Once the exosomes are secreted, they can be internalized from the extracellular space by recipient cells through several mechanisms including phagocytosis, micropinocytosis, endocytosis, and plasma membrane fusion (McKelvey et al., 2015; Figure 1). On the other hand, exosomes carrying multiple cargo with valuable biological information can also be released into most bodily fluids such as plasma, cerebrospinal fluid, urine, saliva, amniotic fluid, colostrum, breast milk, synovial fluid, semen and pleural ascites, not only in normal tissues (Corrado et al., 2013; McKelvey et al., 2015) but also in aberrant bodies such as tumors (Camussi et al., 2011; Rak and Guha, 2012). For the above reasons, exosomes play key roles in the management of normal physiological environments, such as immune surveillance (Rajendran et al., 2006), stem cell maintenance (Ratajczak et al., 2006), tissue repair (Gatti et al., 2011), and blood coagulation (Del et al., 2005), as well as in the pathological processes associated with several diseases (Liu et al., 2019), including neurodegenerative diseases such as AD (Bellingham et al., 2012; Watson et al., 2019) and PD (Emmanouilidou et al., 2010).

Given the characteristic described above, exosomes and their constituents represent a novel class of therapeutic targets and such features also give them advantages as biomarkers to distinguish healthy and disease states (Emmanouilidou et al., 2010) and for prognosis prediction and therapy for diseases. Moreover, recent studies have demonstrated that exosomes may also be directly considered as potential therapeutic agents. For instance, mesenchymal stem cell-derived exosomes have been used in tissue regeneration (Lai et al., 2011; Timmers et al., 2011) and tumor antigen-pulsed dendritic cell-derived exosomes have been developed for cancer immune response modulation (Zitvogel et al., 1998). Remarkably, exosomes have an efficient capability to cross the BBB (Chen et al., 2016). In particular, exosomes isolated from CSF are rich in proteins that originate from the brain such as neuron-specific markers, microglial markers (CD11b and CD45) and Apo-E (Chiasserini et al., 2014), making them potential novel drug delivery vehicles for treating nervous system diseases. Here, we mainly discuss and summarize the role of BDEs in normal biological processes in the CNS as well as the aberrant pathological state of AD and focus on explaining how exosomes can be targeted or directly exploited as biomarkers or therapeutics in AD.

Physiological Roles of BDEs in the CNS

Exosomes exert their effects on essential biological processes throughout the body including the CNS by different mechanisms. These mechanisms include cell surface receptors activation through direct binding to lipid ligands and proteins, exosomal membrane fusion contents with the recipient cell plasma membrane and effectors delivery. Some of these effectors are oncogenes, transcription factors, small and large non-coding regulatory RNAs (such as miRNAs) and mRNAs, as well as infectious particles such as amyloid-β (Aβ)−derived (Bellingham et al., 2012) and α-synuclein (Emmanouilidou et al., 2010) into recipient cells (Camussi et al., 2011; Lee et al., 2012; Figure 1). In this manner, exosomes participate in the maintenance of normal physiology (Figure 2).

FIGURE 2

DeLeo and Ikezu, 2018) along with nucleic acids (DNA, mRNA, miRNA and/or lncRNA and/or cirRNA) (Camussi et al., 2011; Lee et al., 2012; Yokoi et al., 2019). They afford positive as well as negative effect on the neurons depending on the cargo they carry. In the physiological condition, exosomes benefit to the reciprocal communication between neural cells (e.g., neuron-glia interaction), synaptic plasticity, neuronal development and neuroimmune communication. In the early stage of AD, the microglia activation by Aβ has neuroprotective effect because it induces phagocytosis and Aβ clearance (Bolmont et al., 2008; Hickman et al., 2008). The microglia stimulation by astrocyte released ATP induces the secretion of exosomes including P2X7 receptor as a defensive strategy to escape astrocyte signaling (Bolmont et al., 2008; Hickman et al., 2008). In the latter stage of AD, microglia secrete exosomes containing pro-IL1β, active caspase-1 and soluble toxic Aβ that have detrimental effects on neurons (Bianco et al., 2005; Trotta et al., 2018). Neurodegenerative associated proteins such as Aβ, Tau, prions (Faure et al., 2006) and α-synuclein (Emmanouilidou et al., 2010) can also be derived from neural derived exosomes, leading to the spread of protein aggregate seeds and disease progression. In addition, these exosomes could be exported via blood-brain barrier as circulatory EVs, which can be used for disease-specific biomarkers, even future for therapeutic researches (Thompson et al., 2016).

Particularly, in the CNS, exosomes can be released from virtually all cell types, including various types of neurons, astrocytes, oligodendrocytes, microglia, and Schwann cells, as well as endothelial cells (Faure et al., 2006; Sharma et al., 2013). EVs carry and release multiple molecules related to neuronal function and neurotransmission in the brain, which is beneficial for the reciprocal communication between neural cells (e.g., neuron−glia interactions), synaptic plasticity, neuronal development, and neuroimmune communication (Fruhbeis et al., 2013a; Rajendran et al., 2014; Iraci et al., 2016; Table 1).

Neuron-Glia Communication via Exosome Secretion

Neurons and glial cells (a class of cells that mainly includes microglia, astrocytes, and oligodendrocytes) orchestrate CNS homeostasis via numerous mechanisms of intercellular communication. Exosomes might regulate the physiological condition of the recipient cells and interactions between various neural cells. For example, upon activation of glutamatergic synapses, cortical neuron-derived exosomes are selectively delivered to neurons but not glial cells (Koniusz et al., 2016). Recent studies using CD63-GFP positive intraluminal vesicles as exosomal reporter in mice have demonstrated that exosomes participate in mediating neuron to astroglia communication in the CNS (Men et al., 2019). Furthermore, miRNAs (especially miR-124a) in exosomes isolated from neuron-conditioned medium possess excitatory amino acid transporter 2, a necessary mediator of glutamate uptake via the internalization of exosomes into astrocytes (Morel et al., 2013). However, exosomes also participate in reciprocal oligodendrocyte-neuron communication and transfer cargo from oligodendrocytes to neurons (Fruhbeis et al., 2013a). Although exosome-mediated communication and the manner by which exosomes select their recipient cells are largely unclear, emerging evidence suggests that exosomes serve as selectively important conveyers for neuron-neuron or neuron-glia interaction in the brain by transmitting genetic information, various bioactive proteins, and lipids.

Synaptic Plasticity and Neurotransmission by the Release of Exosomes

Maintenance and improvement of synaptic connectivity in the adult brain are crucial for cognitive function. Neural synaptic plasticity is mediated not only by neuron-specific progression but also by glial cells, such as astrocytes and microglia (Morris et al., 2013). Under resting conditions, synaptic vesicles are reposited in the cytoplasm of the nerve terminal. Many synaptic vesicles stick on some specialized sites at the presynaptic plasma membrane named active zones. During incoming action potentials, exocytosis of synaptic vesicles confirm how much transmitter is released from nerve terminals (Jahn and Fasshauer, 2012). In addition to typical synaptic neurotransmission, signal transduction of neurons via the secretion of exosomes can induce a range of neurobiological functions including synaptic plasticity (Chivet et al., 2012; Koniusz et al., 2016). During management of synaptic plasticity, PC12 cell-derived exosomes can stimulate synaptic pruning through enhancement of the complement component 3 level in microglial MG6 cells (Bahrini et al., 2015). For instance, enhanced secretion of cortical neuron-derived exosomes containing neurotransmitter receptors leads to increased glutamatergic activity (Lachenal et al., 2011). Additionally, by managing the number of AMPA receptors for glutamate transmission, neuronal-derived exosomes might affect synaptic plasticity (Lachenal et al., 2011).

Enhancement of Neuron Protection and Neuronal Development Through Exosomes

Although the understanding of astrocyte-neuron communication via exosomes remains unclear, evidence supports that it does occur, and this communication manner is required for neuronal cell survival (Figure 2; Pascua-Maestro et al., 2019; Luarte et al., 2020). Neuroprotective signaling is essential for neuronal growth and survival. PrP is a physiologically important receptor protein that protects against oxidative stress in the CNS. Protection of neurons through astrocyte-derived exosomes is dependent on astrocyte-derived exosomal PrP transport into neurons (Guitart et al., 2016). In addition, studies have demonstrated that microglia and oligodendrocyte-derived exosomes contribute to neuronal energy metabolism by transferring several enzymes involved in energy metabolism (Kramer-Albers et al., 2007; Drago et al., 2017). Thus, exosomes mediate several vital processes involved in normal brain function. Taken together, these findings suggest that exosome-mediated cell communication is emerging as a method of mediating neuron protection.

Pathological Roles of BDEs in AD

Increased secretion of exosomes is generally thought to occur in response to stress or pathological conditions (Urbanelli et al., 2013; Saxton and Sabatini, 2017; Gill et al., 2018), such as hypoxia (King et al., 2012; Ophelders et al., 2016), alcoholism (Momen-Heravi et al., 2015), cisplatin- (Xiao et al., 2014), or irradiation-induced DNA damage (Lehmann et al., 2008), and oxidative stress (Atienzar-Aroca et al., 2016). Neuron-derived exosomes including particular proteins associated with neurodegenerative diseases can be secreted from the affected neurons (Watson et al., 2019). In the case of AD, there are two hallmarks of AD brains, Aβ and hyperphosphorylated tau, interact with specific endosomes and may contribute to exosome biogenesis in AD (Sardar et al., 2018). Additionally, exosomal proteins, such as flotillin-1 and Alix, were observed to accumulate around amyloid plaques in AD patients (Rajendran et al., 2006). The formation, secretion or uptake of exosomes plays a dual role in the spread of oligomers and neurotoxicity (Table 1).

Exosomes Containing Aβ in AD

Amyloid β-protein is a C-terminal cleavage product of the transmembrane APP produced by β- and γ-secretase (Devi and Anandatheerthavarada, 2010; Miranda et al., 2018). AD is characterized by the presence of aggregates of pathologically misfolded proteins in the brain, including extracellular senile plaques mainly consisting of Aβ (Brunkhorst et al., 2014). Numerous reports have described these proteins and their substrates within exosomes of in vitro AD models and in exosomes derived from neurons of AD patients (Dinkins et al., 2014; Yuyama et al., 2015).

Although most AD cases are sporadic, there is a minority patients from mutations in the genes encoding APP or during sequential cleavages by β- and γ-secretase enzyme activities (Chow et al., 2010). In vitro, exosomes isolated from neuronal cell lines show that inducing AD mutations can increase sAPP protein β, sAPPα (Xiao et al., 2017; Sinha et al., 2018) and soluble Aβ1-42 (Eitan et al., 2016a). N2a cells expressing human APP with the autosomal dominant Swedish mutation contain Aβ peptides as well as the C-terminal fragments of APP have also shown increase of production of C-end terminal fragments (a byproduct of APP after β-secretase processing) (Laulagnier et al., 2018), β-secretase in released exosomes, and co-localization of β-secretase enzyme 1 with early exosome markers (Xiao et al., 2017). Vesicles released by Aβ-treated astrocytes contain the pro-apoptotic prostate apoptosis response 4 (PAR-4) protein and these vesicles cause PAR-4 associated apoptosis in naive cultures (Wang et al., 2012). Experiments involving the medium of neural cells expressing familial AD presenilin 1 mutations show that Aβ is associated with exosomes during their excretion process (Eitan et al., 2016b).

In vivo, rodent exosomes can contain Aβ, BACE1, and presenilin 1 and 2 (Sharples et al., 2008). Exosomes isolated from bodily fluids of AD mouse model, including blood, CSF and urine, display indicative increase in the C-terminal fragments of APP (Laulagnier et al., 2018; Miranda et al., 2018). Exosomes isolated from bodily fluids of AD patients exhibit a remarkable increase soluble Aβ1–42 in Abner et al. (2016); Winston et al. (2016), Hamlett et al. (2017, 2018). Amyloid plaques in AD brains also contain an exosome marker (Abner et al., 2016; Winston et al., 2016; Hamlett et al., 2017, 2018). The muskelin protein is involved in reorganization of the cytoskeleton and has been shown to be involved in the determination of either lysosomal degradation or exosome secretion of PrP (Heisler et al., 2018). Importantly, PrP is a receptor for Aβ and is reported to increase the pathogenicity of AD (Cohen et al., 2016). Muskelin may play a critical role in this type of amyloidosis.

The above data suggested the hypothesis that exosomes could seed Aβ aggregation (Dinkins et al., 2017). However, neuronal exosomes can also restrain Aβ oligomerization and accelerate Aβ fibril formation, facilitating microglia-mediated Aβ clearance in vitro (Yuyama et al., 2012). Moreover, in an AD mouse model, intracerebral loading of glycosphingolipid-enriched exosomes led to trapping and transporting Aβ into microglia, leading to a decrease in Aβ pathology (Yuyama et al., 2014). These results might explain why, at least under some circumstances, exosomes associated with Aβ have a physiological, neuroprotective function (Yuyama and Igarashi, 2017). It is also possible that in the brain as exosomes are secreted by various cell types (e.g., neurons, microglia, and astrocytes), they might exhibit contrary effects or the exosomal membranes might promote Aβ aggregation independent of protein-associated exosomal functions (e.g., Aβ degradation by exosomal insulin-degrading neprilysin or enzymes) (reviewed in Dinkins et al., 2017).

Exosomes Containing Hyperphosphorylated Tau in AD

The gradual deposition of hyperphosphorylated tau protein within specific neurons is pivotal to the tauopathy of AD (Saman et al., 2014; Takeda, 2019). Under normal physiological conditions, incorporation of neuronal microtubule-associated protein tau for microtubule elongation is a crucial event of neuronal synapse formation and synaptic plasticity. Additionally, intracellular tau also participates in neurite outgrowth, axonal transport, chromosome stability, regulation the cellular transcriptome and the structural architecture of heterochromatin (for more details see the review by Sotiropoulos et al., 2017). Extracellular tau is also secreted into brain interstitial fluid (Yamada et al., 2011) and may contribute to some characteristics of sleep (Lucey et al., 2019). The above functions rely on the site-specific phosphorylation of tau (Kapitein and Hoogenraad, 2015) in normal condition. However, hyperphosphorylation and aggregation of the microtubule-associated tau protein into intracellular neurofibrillary tangles is one of the classical pathological hallmarks of advanced-stage AD (Johnson and Stoothoff, 2004; Martin et al., 2011).

During the progressive accumulation of neurofibrillary tangles, tau becomes hyperphosphorylated in neurons. Meanwhile, the cellular clearance machinery takes up tau for degradation and packaging in exosomes (Saman et al., 2012; Chesser et al., 2013; Perez et al., 2019). In an adeno-associated virus-based mouse model revealing rapid tau propagation, microglia help to spread tau through exosome release, and depletion of microglia or inhibition of exosome synthesis significantly decreases the propagation of tau in vitro and in vivo (Asai et al., 2015). In another mouse model of tauopathy, aggregated tau was isolated from and transmitted through brain exosomes (Asai et al., 2015). In these mice, exosomes that were isolated from the brains of tau transgenic rTg4510 mice containing human four-repeat tau with the P301L mutation accelerated pathological tau phosphorylation and oligomer formation (Polanco et al., 2016), indicating that neuronal exosomes containing human mutated tau are toxic to the recipient neurons in vivo (Baker et al., 2016). Recently, BIN1 was found to support spreading of tau via exosome release in mice. Tau-containing exosomes isolated from the CSF of AD-affected individuals who contain BIN1-associated genetic variants in AD etiology showed seeding competence (Crotti et al., 2019). In human patients, compared with BDEs obtained from the plasma or serum of age-matched controls, BDEs from AD patients showed a 3-20-fold increase in tau phosphorylation at threonine 181 (p-T181-tau) and serine 396 (p-S396-tau) (Crotti et al., 2019). Moreover, compared with AD patients who had only been diagnosed with mild cognitive impairment, p-T181-tau levels were significantly higher in BDEs isolated from the plasma of later-stage AD patients (Winston et al., 2016), demonstrating either a dysfunction of the clearance ability or an increase in pathogenicity of exosomes in later disease states of AD. p-T181- and p-S396-tau were significantly decreased in BDEs of patients 1–10 years prior to their AD diagnosis (Fiandaca et al., 2015).

Exosomes Containing Synaptic Proteins in AD

One consequence of AD is neuron loss and dysfunction. The levels of synaptic proteins, including synaptophysin, synaptotagmins, synaptobrevin, synaptopodin, Rab3A, GAP 43, and neurogranin, were decreased in the BDE cargo from the plasma of AD patients (Goetzl et al., 2016b). Additionally, low-density LRP 6, REST, heat shock factor protein 1, HSP, and AMPA receptor levels are also lower in BDEs from the plasma of AD patients (Goetzl et al., 2015, 2016b; Winston et al., 2016). Furthermore, neurexin 2α, GluA4-containing glutamate receptor, and neuroligin 1, essential proteins for long-term potentiation processes, were all significantly reduced in BDEs from the plasma of patients 6−11 years prior to AD diagnosis and, along with neuronal pentraxin 2, were all downregulated in BDEs (Goetzl et al., 2018, 2019). These proteins are all involved in normal homeostasis of neurons. Further research into these proteins in BDEs could be beneficial for the search for earlier biomarkers of AD.

Ceramide and Sphingosine-1-Phosphate (S1P) in Exosomes in AD

Activated sphingolipids are signaling molecules that serve as intracellular second messengers and include ceramide, sphingosine, and their derivatives, 1-phosphates (C1P and S1P, respectively) (Czubowicz et al., 2019). Exosomes are sphingomyelin- and ceramide-enriched vesicles formed inside MVEs and then are secreted when the MVE membrane fuses with the plasmalemma. Exosomes can serve as a vehicle for the extracellular secretion and cell-to-cell transport of Aβ, α-synuclein and tau protein, possibly further facilitating the spread of toxic protein aggregation (Ngolab et al., 2017; Wang et al., 2017). S1P receptor (S1PR) signaling has been reported to participate in exosomal cargo sorting. Activity of the S1PR-mediated Rho family of GTPases is essential for this process and Gβγ inhibitors inhibit this activity (Kajimoto et al., 2018). The secretion of exosomes can be regulated by the activation of neutral sphingomyelin synthase 2 (SMS2) and sphingomyelinase 2 (nSMase2), demonstrating distinct functions for these enzymes in AD (Yuyama et al., 2012; Dinkins et al., 2014). Additionally, ceramide/sphingolipid shortage results in enhanced secretion of sAβPPα, the product of non-amyloidogenic cleavage. However, this shortage gives rise to increased secretion of Aβ42 at the same time, probably via regulation of raft-associated proteins, resulting in alteration of the α- vs.β-cleavage ratio (Yuyama et al., 2012; Dinkins et al., 2014). Enhanced endogenous ceramide and exogenous additional ceramide both elevate the Aβ level (Puglielli et al., 2003; Sawamura et al., 2004). The above research suggests the significance of the ceramide/sphingolipid levels in the process of AD.

Exosomes Containing Other AD-Associated Proteins

Dysregulation of insulin by the CNS and peripheral hyperinsulinemia have been reported as other events highly associated with AD (de la Monte, 2009; de la Monte and Tong, 2014; Kim et al., 2015). A low tyrosine phosphorylated insulin receptor substrate 1 (IRS1) to serine phosphorylated IRS1 ratio is a characteristic of insulin dysregulation (Aguirre et al., 2002; Draznin, 2006) and is related to greater brain atrophy in AD patients (Mullins et al., 2017). BDEs isolated from the plasma of human AD patients have revealed an enhancement in serine phosphorylation in IRS1 (Kapogiannis et al., 2015). This study demonstrated that significant differences in the IRS1 levels were recognizable up to 10 years prior to clinical onset of AD, which suggests that proteins within BDEs that are involved in insulin disruption may potentially be useful biomarkers for clinical diagnosis.

Moreover, exosomes have the ability to spread toxic proteins through PrP activity (Hartmann et al., 2017). PrP is a cell surface-anchored protein that is highly related to AD pathology (Kellett and Hooper, 2009). Its pathological, misfolded form is associated with spongiform encephalopathy (Prusiner, 1982; Song et al., 2013). Studies in animal models of AD have demonstrated that the PrP receptor is essential for the cognitive impairment linked to Aβ (Gimbel et al., 2010). Additionally, growing evidence indicates that prion receptor on exosomes are capable of transmitting pathological substances (Fevrier et al., 2004; Hartmann et al., 2017). Aberrant autophagy is likely to play a role in this process (Abdulrahman et al., 2018). However, further research is needed to explore the potential mechanism connecting exosomes, AD pathogenesis, and autophagy.

Exosomal MiRNA as a Diagnostic Biomarker for AD

Generally, the biomarkers used for AD diagnosis include the expression of Aβ and pTau (Abdulrahman et al., 2018), and methods such as neuropsychological testing and specialized brain imaging techniques have also been widely used for diagnosis of AD. Unfortunately, most AD patients are asymptomatic during the pre-clinical stages, which may last up to 17 years or longer (Villemagne et al., 2013). Therefore, it is important to exploit early diagnostics to confirm and treat individuals who are at risk before severe and irreversible neuronal pathology occurs.

MiRNAs are a family of 18–22 nt single-stranded RNAs that post-translationally communicate with and regulate the expression of mature mRNAs. Single upregulated miRNAs can target various mRNAs to decrease their expression and multiple miRNAs can target a single mRNA (Sethi and Lukiw, 2009; Sarkar et al., 2016). Studies have demonstrated that mRNA and miRNA species are present in exosomes. It is possible that some mRNA sequences are definitely targeted for secretion by these vesicles (Valadi et al., 2007; Van Giau and An, 2016). Exosomal miRNAs play essential roles in intercellular communication between cell membranes in the CNS and in disease progression. Exosomal miRNAs are also ideal targets for use as potential biomarkers in clinical diagnostics or therapies as they can be analyzed through neuronal exosomes in the patient’s body fluids (A). Indeed, some research has illustrated that proteins and miRNAs can be transferred from glia to axons (Skog et al., 2008). It is assumed that miRNA signaling can impact neurodegenerative diseases via the dysregulation of tau, leading to neurotoxicity. One study convincingly demonstrated that, in brain tissues obtained at autopsy from AD patients and from those with severe primary age-related tau pathology, the level of the highly conserved miRNA-219 was decreased in the brain (Santa-Maria et al., 2015). Several reports have illustrated that high expression of tissue-specific miRNAs in the brain, such as miR-9, miR-29a/b, miR-107, miR-124, miR-128, miR-134, and miR-137, may result in defective neuronal development (Sempere et al., 2004; Kawase Koga et al., 2009; Huang et al., 2010). In addition, other miRNAs are also abnormal in brain tissues during neurodegenerative processes. These specific miRNAs, including miR-132 and miR-212, are among the most robustly declining miRNAs in neurodegenerative diseases, including AD (Cogswell et al., 2008; Hebert et al., 2013; Wong et al., 2013; Lau et al., 2014), Huntington’s disease (Johnson et al., 2008; Packer et al., 2008), PD (Burgos et al., 2014), schizophrenia and bipolar disorders (Perkins et al., 2007; Kim et al., 2010) and frontotemporal dementia (Chen-Plotkin et al., 2012; Hebert et al., 2013).

Remarkably, miRNAs that were found to be greatly expressed in the brain were also detected in human body fluids such as the plasma, urine, and CSF. The levels of brain-enriched miRNAs including miR-9, miR-29a, miR-29b, and miR-137 have been found to be significantly decreased in plasma samples collected from AD patients (Geekiyanage et al., 2012). Both miR-128 and miR-134 were also examined in patients with mild cognitive impairment, which is an early stage of AD (Sheinerman et al., 2012). These miRNA biomarkers in the blood represents a clinical advantage for early disease diagnosis, but differential miRNA expression may not accurately rescue abnormal miRNA expression in the brain. The CSF represents a more relevant and suitable source for the diagnosis of CNS disorders such as AD (Alexandrov et al., 2012; Patz et al., 2013; Van Giau and An, 2016) because CSF is a clear biological fluid produced in the choroid plexus of the brain that circulates via the inner ventricular system, crosses the BBB, and is absorbed into the bloodstream. The levels of target candidate miRNAs such as miR-9, miR-146a, and miR-155 were shown to be greatly increased in CSF from AD patients compared with those in age-matched controls, as quantified by microarrays and qRT-PCR (Alexandrov et al., 2012; Lukiw et al., 2012). Currently, urine is collected and analyzed for biomarker discovery and diagnostic purposes in clinical practice (Weber et al., 2010; Bryant et al., 2012). Exosomes can be purified from the urine using various methods such as differential ultracentrifugation (Alvarez et al., 2012), which is highly valuable for investigating whether miRNAs can be detected in the urine. However, it remains difficult to determine whether the alteration in miRNA levels in humans is a cause or consequence of the neurodegenerative process. Investigation of miRNA analysis profiles in AD animal models might help to solve this problem. Additionally, the potential to test miRNAs in biological body fluids may contribute to developing and promoting the discovery of specific biomarkers for neurodegenerative diseases such as AD.

Development of a Brain-Derived Exosomal Biomarker for AD

Currently, a mixed population of exosomes from various types of cells can be separated from biological fluids by multiple techniques such as classically differential ultracentrifugation, immunomagnetic beads and size exclusion chromatography (Li et al., 2017; Yu et al., 2018). Moreover, exosomes have a lipid bilayer to protect their cargo, which is used downstream, from RNAse treatment to be confirmed whether the miRNAs/mRNA analyzed are inside the exosomes or not (Cheng et al., 2014). This mixed population of exosomes may be recognized by western blots or mass spectrometry using proteins that are involved in the formation process of ILVs (Lotvall et al., 2014) as mentioned and discussed at the beginning of this manuscript. It is worth noting that many of these markers are not exclusive to exosomes and it is necessary to further examine the characteristics of exosomes (Watt et al., 2011). In the CNS, investigating cells from the brain may afford insights into the mechanisms of brain diseases (Saeedi et al., 2019). Isolating neuronal exosomes from cells related to AD may bridge the gaps in knowledge of peripheral biomarkers and provide mechanistic insight to this disease. Recently, a precipitation/immunoaffinity system has been developed to isolate neuron-derived and astrocyte-derived exosomes from the blood of AD patients (Goetzl et al., 2018). Data from these studies suggest that BDEs from blood plasma and measurement of certain forms of tau in BDEs can be used as diagnostic and prognostic biomarkers for AD (Guix et al., 2018; Saeedi et al., 2019).

Enrichment of a specific neuron-derived population of exosomes permits monitoring of target cells of interest (Table 2). Collectively, although exosome transfer of Aβ seems to mainly occur in AD and can be exploited as a helpful biomarker of the disease course, development of additional exosome biomarkers could contribute to a more accurate diagnosis of AD and discovering further close connections between the marker and mechanisms of the early stage of AD as well as other neurodegenerative diseases.

Exosomes as Novel AD Therapeutics

The BBB is a continuous endothelial membrane within brain microvessels and is sheathed by mural vascular cells and perivascular astrocyte end-feet, which seal the cell−to−cell contacts to prevent the transmission of potentially toxic compounds between the brain and the blood (Matsumoto et al., 2017). In addition to transmembrane diffusion of small (<400 Da) lipid-soluble molecules, the BBB permits selective transport of some compounds into and out of the brain (Sanchez-Covarrubias et al., 2014).

Exosomes have an inherent ability to cross the BBB, and because their properties remain active in the brain, they are ideal drug delivery vehicles. This BBB-penetrating capacity, which was first reported by Alvarez-Erviti et al. (2011), resulted in effective delivery of small-molecule drugs to the brain through systemic injection of naked exosomes in mice, leading to promotion of drug-mediated biological responses (Zhuang et al., 2011). Later studies have been successful in transmitting exosomes through intranasal injection into the mouse brain (Aliotta et al., 2007). Recently, a study using rats identified that the fluorescently tagged forebrain astrocyte protein aldolase C was selectively expressed in brain tissue and could be recovered in exosomes in the blood (Ratajczak et al., 2006; Gomez-Molina et al., 2019). This study affords evidence of communication mediated by exosomes from the brain to the rest of the body (Ratajczak et al., 2006; Gomez-Molina et al., 2019). Evidence from these studies illustrates that exosomes can cross the BBB in a bi-directional manner; however, their method of accurately crossing the BBB remains unclear and requires further study.

In contrast, while exosomes may play a role in the spreading of AD, some studies have shown a positive effect of introducing non-pathogenic exosomes to change disease duration and progression (Table 3). In animal studies, this therapeutic effect was found when exosomes from young mice were observed to significantly downregulate aging-associated signaling molecules such as IGF1R and upregulate telomerase-related genes such as Men1, Mre11a, Tep1, Terf2, Tert, and Tnks in aged mice (Lee et al., 2018). Furthermore, exosomes injected into the brain of transgenic mouse models of AD can help to decrease toxic oligomers and fibrils in a microglial-dependent manner following intracerebral administration, contributing to the clearance of Aβ in vivo (Yuyama et al., 2012, 2014; Yuyama and Igarashi, 2017). Other researchers have suggested that mesenchymal stromal-derived exosomes may have a therapeutic effect in vivo on the advancement of neurovascular plasticity in other neurodegenerative diseases such as stroke (Xin et al., 2013a).

Additionally, directed exosomal transmission systems for precision nanomedicine have attracted extensive interest across the fields of pharmaceutical sciences, molecular cell biology and nanoengineering (Zhu et al., 2018). Exosomes are also a promising type of novel drug delivery vehicle because of their ability to cross the BBB and shield their cargo from enzymatic and chemical degradation. Recent developments regarding nanoengineering using targeted exosomes for therapeutic purposes have been conducted by researchers, for example, Xin et al. (2013b), Tran et al. (2019).

Introducing exogenous exosomes into the CNS because they can effectively cross the BBB is a potentially novel strategy for AD therapies (Chen et al., 2016), and their innate secretion of enzymes could be beneficial for degrading toxic fibrils (Katsuda et al., 2015). The field of EV research is still at the initial stage in the CNS and yet improved therapeutic applications are already being developed.

Opportunities and Challenges

Quantifying changes in EV cargo would be extremely difficult because of the lack of unique region-specific markers for circulating exosomes and the inaccessibility of specific brain tissue EVs from living patients. Interesting lines of research have examined both the induction of AD using pathogenic EVs and the sequestration of toxic plaques using exogenous healthy EVs.

It difficult to distinguish among EV types simply on the basis of protein markers or size alone. To better interpret and replicate the experimental results of exosome studies, combined exosome isolation methods as well as improved techniques for accurate purification and characterization are recommended. In addition, a crowdsourcing knowledgebase currently allows researchers in the EV field to track the latest EV biology and methodology (Lee et al., 2019).

In recent years, research has been focused on BDEs to attempt to solve questions of brain-associated disorders using blood biopsies. Exosomes isolated from plasma were used to enrich BDEs (Sun et al., 2017; Saeedi et al., 2019). This study demonstrated that both the number of neural-derived exosomes as well as the expression of Aβ, neurofilament light chain, and high-mobility group box 1 potentially act as biomarkers of neuropsychological impairment in HIV (Sun et al., 2017). BDEs from plasma have also been tested in a pilot study to examine protein biomarkers for patients with major depressive disorder (Kuwano et al., 2018). Moreover, in military personal with mild traumatic brain injuries, compared with controls, the levels of tau, Aβ42, and IL-10 deposited by BDEs were elevated (Kuwano et al., 2018). Cargo proteins and miRNA from astrocytic-derived exosomes have been analyzed to obtain mechanistic insight into AD (Goetzl et al., 2016b). Additionally, other cell-derived exosomes have also been researched for other brain-related disorders. The ability to access BDEs in plasma and other biological body fluids such as CSF and urine shows potential for clinical use in treating nervous system disorders.

Conclusion

Although the domain of exosome investigation, especially BDEs, remains relatively novel, attractive evidence from other fields demonstrates that investigation of exosomes can afford insight into the disease mechanisms and processes associated with AD and treatment responses. Currently, increased research on exosomes has focused on biomarkers of the course of AD and their ability to mediate cell-to-cell communication in the nervous system. However, additional work is needed with respect to the mechanisms of bi-directional transport of cargo-carrying exosomes across the BBB, the alterations in the number or size of exosomes secreted, changes in cargo constituents, and identification of differences in specific cell types. Meantime, it is necessary to take into consideration that several preparations may contain another type of EVs given the procedure used to obtain them. Exosomes derived from cells in the CNS have tremendous biomarker potential because they may reverse physiological changes in nervous system disorders, and these changes can be tested in the periphery.

References

• 1

  AbdulrahmanB. A.AbdelazizD. H.SchatzlH. M. (2018). Autophagy regulates exosomal release of prions in neuronal cells.J. Biol. Chem.2938956–8968. 10.1074/jbc.RA117.000713

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  AbnerE. L.JichaG. A.ShawL. M.TrojanowskiJ. Q.GoetzlE. J. (2016). Plasma neuronal exosomal levels of Alzheimer’s disease biomarkers in normal aging.Ann. Clin. Transl. Neurol.3399–403. 10.1002/acn3.309

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  AguirreV.WernerE. D.GiraudJ.LeeY. H.ShoelsonS. E.WhiteM. F. (2002). Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action.J. Biol. Chem.2771531–1537. 10.1074/jbc.M101521200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  AlexandrovP. N.DuaP.HillJ. M.BhattacharjeeS.ZhaoY.LukiwW. J. (2012). microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF).Int. J. Biochem. Mol. Biol.3365–373.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 5

  AliottaJ. M.Sanchez-GuijoF. M.DoonerG. J.JohnsonK. W.DoonerM. S.GreerK. A.et al (2007). Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation.Stem Cells252245–2256. 10.1634/stemcells.2007-0128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  AlvarezM. L.KhosroheidariM.KanchiR. R.DiStefanoJ. K. (2012). Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers.Kidney Int.821024–1032. 10.1038/ki.2012.256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  Alvarez-ErvitiL.SeowY.YinH.BettsC.LakhalS.WoodM. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.Nat. Biotechnol.29341–345. 10.1038/nbt.1807

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  AnK.KlyubinI.KimY.JungJ. H.MablyA. J.O’DowdS. T.et al (2013). Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo.Mol:Brain647. 10.1186/1756-6606-6-47

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  AsaiH.IkezuS.TsunodaS.MedallaM.LuebkeJ.HaydarT.et al (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation.Nat. Neurosci.181584–1593. 10.1038/nn.4132

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  Atienzar-ArocaS.Flores-BellverM.Serrano-HerasG.Martinez-GilN.BarciaJ. M.AparicioS.et al (2016). Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells.J. Cell. Mol. Med.201457–1466. 10.1111/jcmm.12834

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  BahriniI.SongJ. H.DiezD.HanayamaR. (2015). Neuronal exosomes facilitate synaptic pruning by up-regulating complement factors in microglia.Sci. Rep.5:7989. 10.1038/srep07989

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  BakerS.PolancoJ. C.GotzJ. (2016). Extracellular vesicles containing P301L mutant tau accelerate pathological tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 mice.J. Alzheimers Dis.541207–1217. 10.3233/JAD-160371

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  BellinghamS. A.GuoB. B.ColemanB. M.HillA. F. (2012). Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?Front. Physiol.3:124. 10.3389/fphys.2012.00124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  BiancoF.PravettoniE.ColomboA.SchenkU.MöllerT.MatteoliM.et al (2005). Astrocyte-Derived ATP induces vesicle shedding and IL-1β release from microglia.J. Immunol.174:7268. 10.4049/jimmunol.174.11.7268

  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  BolmontT.HaissF.EickeD.RaddeR.MathisC. A.KlunkW. E.et al (2008). Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance.J. Neurosci.28:4283. 10.1523/JNEUROSCI.4814-07.2008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  BrunkhorstR.VutukuriR.PfeilschifterW. (2014). Fingolimod for the treatment of neurological diseases-state of play and future perspectives.Front. Cell. Neurosci.8:283. 10.3389/fncel.2014.00283

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  BryantR. J.PawlowskiT.CattoJ. W.MarsdenG.VessellaR. L.RheesB.et al (2012). Changes in circulating microRNA levels associated with prostate cancer.Br. J. Cancer106768–774. 10.1038/bjc.2011.595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  BullerB.MooreT.ZhangY.PikulaE.MartinC.MortazaviF.et al (2016). Exosomes from rhesus monkey MSCs promote neuronal growth and myelination.Stroke47:A68.

  • Google Scholar
  • View reference in article

• 19

  BurgosK.MalenicaI.MetpallyR.CourtrightA.RakelaB.BeachT.et al (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology.PLoS One9:e94839. 10.1371/journal.pone.0094839

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  CamussiG.DeregibusM. C.BrunoS.GrangeC.FonsatoV.TettaC. (2011). Exosome/microvesicle-mediated epigenetic reprogramming of cells.Am. J. Cancer Res.198–110.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 21

  ChenC. C.LiuL.MaF.WongC. W.GuoX. E.ChackoJ. V.et al (2016). Elucidation of exosome migration across the blood-brain barrier model in vitro.Cell. Mol. Bioeng.9509–529. 10.1007/s12195-016-0458-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  ChengL.SharplesR. A.SciclunaB. J.HillA. F. (2014). Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood.J. Extracell Vesicles3:23743. 10.3402/jev.v3.23743

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  Chen-PlotkinA. S.UngerT. L.GallagherM. D.BillE.KwongL. K.Volpicelli-DaleyL.et al (2012). TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.J. Neurosci.3211213–11227. 10.1523/JNEUROSCI.0521-12.2012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  ChesserA. S.PritchardS. M.JohnsonG. V. (2013). Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.Front. Neurol.4:122. 10.3389/fneur.2013.00122

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  ChiasseriniD.van WeeringJ. R.PiersmaS. R.PhamT. V.MalekzadehA.TeunissenC. E.et al (2014). Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.J. Proteomics106191–204. 10.1016/j.jprot.2014.04.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  ChivetM.HemmingF.Pernet-GallayK.FrabouletS.SadoulR. (2012). Emerging role of neuronal exosomes in the central nervous system.Front. Physiol.3:145. 10.3389/fphys.2012.00145

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  ChowV. W.MattsonM. P.WongP. C.GleichmannM. (2010). An Overview of APP Processing Enzymes and Products.Neuromol. Med.121–12. 10.1007/s12017-009-8104-z

  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  CicognolaC.BrinkmalmG.WahlgrenJ.PorteliusE.GobomJ.CullenN. C.et al (2019). Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease.Acta Neuropathol.137279–296. 10.1007/s00401-018-1948-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  CogswellJ. P.WardJ.TaylorI. A.WatersM.ShiY.CannonB.et al (2008). Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways.J. Alzheimers Dis.1427–41. 10.3233/jad-2008-14103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  CohenM.ApplebyB.SafarJ. G. (2016). Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer’s disease.Prion109–17. 10.1080/19336896.2015.1123371

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  ColomboM.RaposoG.TheryC. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.Annu. Rev. Cell Dev. Biol.30255–289. 10.1146/annurev-cellbio-101512-122326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 32

  CorradoC.RaimondoS.ChiesiA.CicciaF.De LeoG.AlessandroR. (2013). Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications.Int. J. Mol. Sci.145338–5366. 10.3390/ijms14035338

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 33

  CrottiA.SaitH. R.McAvoyK. M.EstradaK.ErgunA.SzakS.et al (2019). BIN1 favors the spreading of Tau via extracellular vesicles.Sci. Rep.9:9477. 10.1038/s41598-019-45676-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 34

  CuiG.WuJ.MouF.XieW.WangF.WangQ.et al (2018). Exosomes derived from hypoxia-preconditioned mesenchymal stromal cells ameliorate cognitive decline by rescuing synaptic dysfunction and regulating inflammatory responses in APP/PS1 mice.FASEB J.32654–668. 10.1096/fj.201700600R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 35

  CzubowiczK.JeskoH.WencelP.LukiwW. J.StrosznajderR. P. (2019). The role of ceramide and sphingosine-1-phosphate in Alzheimer’s disease and other neurodegenerative disorders.Mol. Neurobiol.565436–5455. 10.1007/s12035-018-1448-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 36

  de la MonteS. M. (2009). Insulin resistance and Alzheimer’s disease.BMB Rep.42475–481. 10.5483/bmbrep.2009.42.8.475

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 37

  de la MonteS. M.TongM. (2014). Brain metabolic dysfunction at the core of Alzheimer’s disease.Biochem. Pharmacol.88548–559. 10.1016/j.bcp.2013.12.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 38

  DelC. I.ShrimptonC. N.ThiagarajanP.LopezJ. A. (2005). Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.Blood1061604–1611. 10.1182/blood-2004-03-1095

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 39

  DeLeoA. M.IkezuT. (2018). Extracellular vesicle biology in Alzheimer’s disease and related tauopathy.J. Neuroimmune Pharmacol.13292–308. 10.1007/s11481-017-9768-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 40

  DeviL.AnandatheerthavaradaH. K. (2010). Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer’s and Parkinson’s diseases.Biochim. Biophys. Acta180211–19. 10.1016/j.bbadis.2009.07.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 41

  DingM.ShenY.WangP.XieZ.XuS.ZhuZ.et al (2018). Exosomes Isolated From Human Umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in Alzheimer’s Disease.Neurochem. Res.432165–2177. 10.1007/s11064-018-2641-5

  • CrossRef
  • Google Scholar
  • View reference in article

• 42

  DinkinsM. B.DasguptaS.WangG.ZhuG.BieberichE. (2014). Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease.Neurobiol. Aging351792–1800. 10.1016/j.neurobiolaging.2014.02.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 43

  DinkinsM. B.WangG.BieberichE. (2017). Sphingolipid-enriched extracellular vesicles and Alzheimer’s disease: a decade of research.J. Alzheimers Dis.60757–768. 10.3233/JAD-160567

  • CrossRef
  • Google Scholar
  • View reference in article

• 44

  DragoF.LombardiM.PradaI.GabrielliM.JoshiP.CojocD.et al (2017). ATP modifies the proteome of extracellular vesicles released by microglia and influences their action on astrocytes.Front. Pharmacol.8:910. 10.3389/fphar.2017.00910

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 45

  DrazninB. (2006). Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin.Diabetes552392–2397. 10.2337/db06-0391

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 46

  EitanE.HutchisonE. R.MarosiK.ComottoJ.MustapicM.NigamS. M.et al (2016a). Extracellular vesicle-associated Aβ mediates trans-neuronal bioenergetic and Ca 2+-handling deficits in Alzheimer’s disease models.NPJ Aging Mech. Dis.2:16019. 10.1038/npjamd.2016.19

  • CrossRef
  • Google Scholar
  • View reference in article

• 47

  EitanE.SuireC.ZhangS.MattsonM. P. (2016b). Impact of lysosome status on extracellular vesicle content and release.Ageing Res. Rev.3265–74. 10.1016/j.arr.2016.05.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 48

  EmmanouilidouE.MelachroinouK.RoumeliotisT.GarbisS. D.NtzouniM.MargaritisL. H.et al (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.J. Neurosci.306838–6851. 10.1523/JNEUROSCI.5699-09.2010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 49

  FaureJ.LachenalG.CourtM.HirrlingerJ.Chatellard-CausseC.BlotB.et al (2006). Exosomes are released by cultured cortical neurones.Mol. Cell. Neurosci.31642–648. 10.1016/j.mcn.2005.12.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 50

  FevrierB.ViletteD.ArcherF.LoewD.FaigleW.VidalM.et al (2004). Cells release prions in association with exosomes.Proc. Natl. Acad. Sci. U.S.A.1019683–9688. 10.1073/pnas.0308413101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 51

  FiandacaM. S.KapogiannisD.MapstoneM.BoxerA.EitanE.SchwartzJ. B.et al (2015). Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study.Alzheimers Dement.11600–607.e1. 10.1016/j.jalz.2014.06.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 52

  FruhbeisC.FrohlichD.KuoW. P.AmphornratJ.ThilemannS.SaabA. S.et al (2013a). Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication.PLoS Biol.11:e1001604. 10.1371/journal.pbio.1001604

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 53

  FruhbeisC.FrohlichD.KuoW. P.Kramer-AlbersE. M. (2013b). Extracellular vesicles as mediators of neuron-glia communication.Front. Cell. Neurosci.7:182. 10.3389/fncel.2013.00182

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 54

  GattiS.BrunoS.DeregibusM. C.SordiA.CantaluppiV.TettaC.et al (2011). Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury.Nephrol. Dial Transplant.261474–1483. 10.1093/ndt/gfr015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 55

  GeekiyanageH.JichaG. A.NelsonP. T.ChanC. (2012). Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease.Exp. Neurol.235491–496. 10.1016/j.expneurol.2011.11.026

  • CrossRef
  • Google Scholar
  • View reference in article

• 56

  GillJ.MustapicM.Diaz-ArrastiaR.LangeR.GulyaniS.DiehlT.et al (2018). Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel.Brain Inj.321277–1284. 10.1080/02699052.2018.1471738

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 57

  GimbelD. A.NygaardH. B.CoffeyE. E.GuntherE. C.LaurenJ.GimbelZ. A.et al (2010). Memory impairment in transgenic Alzheimer mice requires cellular prion protein.J. Neurosci.306367–6374. 10.1523/JNEUROSCI.0395-10.2010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 58

  GiriP. K.KruhN. A.DobosK. M.SchoreyJ. S. (2010). Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis−infected and culture filtrate protein−treated macrophages.Proteomics103190–3202. 10.1002/pmic.200900840

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 59

  GiriP. K.SchoreyJ. S. (2008). Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo.PLoS One3:e2461. 10.1371/journal.pone.0002461

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 60

  GoetzlE. J.AbnerE. L.JichaG. A.KapogiannisD.SchwartzJ. B. (2018). Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer’s disease.FASEB J.32888–893. 10.1096/fj.201700731R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 61

  GoetzlE. J.BoxerA.SchwartzJ. B.AbnerE. L.PetersenR. C.MillerB. L.et al (2015). Low neural exosomal levels of cellular survival factors in Alzheimer’s disease.Ann. Clin. Transl. Neurol.2769–773. 10.1002/acn3.211

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 62

  GoetzlE. J.KapogiannisD.SchwartzJ. B.LobachI. V.GoetzlL.AbnerE. L.et al (2016a). Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease.FASEB J.304141–4148. 10.1096/fj.201600816R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 63

  GoetzlE. J.MustapicM.KapogiannisD.EitanE.LobachI. V.GoetzlL.et al (2016b). Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease.FASEB J.303853–3859. 10.1096/fj.201600756R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 64

  GoetzlE. J.Nogueras-OrtizC.MustapicM.MullinsR. J.AbnerE. L.SchwartzJ. B.et al (2019). Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease.FASEB J.33231–238. 10.1096/fj.201801001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 65

  Gomez-MolinaC.SandovalM.HenziR.RamirezJ. P.Varas-GodoyM.LuarteA.et al (2019). Small extracellular vesicles in rat serum contain astrocyte-derived protein biomarkers of repetitive stress.Int. J. Neuropsychopharmacol.22232–246. 10.1093/ijnp/pyy098

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 66

  GuitartK.LoersG.BuckF.BorkU.SchachnerM.KleeneR. (2016). Improvement of neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic conditions depends on prion protein.Glia64896–910. 10.1002/glia.22963

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 67

  GuixF. X.CorbettG. T.ChaD. J.MustapicM.LiuW.MengelD.et al (2018). Detection of aggregation-competent tau in neuron-derived extracellular vesicles.Int. J. Mol. Sci.19:663. 10.3390/ijms19030663

  • CrossRef
  • Google Scholar
  • View reference in article

• 68

  HamlettE. D.GoetzlE. J.LedreuxA.VasilevkoV.BogerH. A.LaRosaA.et al (2017). Neuronal exosomes reveal Alzheimer’s disease biomarkers in Down syndrome.Alzheimers Dement.13541–549. 10.1016/j.jalz.2016.08.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 69

  HamlettE. D.LedreuxA.PotterH.ChialH. J.PattersonD.EspinosaJ. M.et al (2018). Exosomal biomarkers in Down syndrome and Alzheimer’s disease.Free Radic. Bio. Med.114110–121. 10.1016/j.freeradbiomed.2017.08.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  HanY.SeyfriedD.MengY.YangD.SchultzL.ChoppM.et al (2018). Multipotent mesenchymal stromal cell–derived exosomes improve functional recovery after experimental intracerebral hemorrhage in the rat.J. Neurosurg.131290–300. 10.3171/2018.2.JNS171475

  • CrossRef
  • Google Scholar

• 71

  HartmannA.MuthC.DabrowskiO.KrasemannS.GlatzelM. (2017). Exosomes and the prion protein: more than one truth.Front. Neurosci.11:194. 10.3389/fnins.2017.00194

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  HebertS. S.WangW. X.ZhuQ.NelsonP. T. (2013). A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer’s disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls.J. Alzheimers Dis.35335–348. 10.3233/JAD-122350

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  HeijnenH. F.SchielA. E.FijnheerR.GeuzeH. J.SixmaJ. J. (1999). Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.Blood943791–3799.

  • Pubmed Abstract
  • Google Scholar

• 74

  HeislerF. F.PechmannY.WieserI.AltmeppenH. C.VeenendaalL.MuhiaM.et al (2018). Muskelin coordinates PrPC lysosome versus exosome targeting and impacts prion disease progression.Neuron991155.–1169. 10.1016/j.neuron.2018.08.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  HickmanS. E.AllisonE. K.El KhouryJ. (2008). Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer&#039;s disease mice.J. Neurosci.28:8354. 10.1523/JNEUROSCI.0616-08.2008

  • CrossRef
  • Google Scholar

• 76

  HuangT.LiuY.HuangM.ZhaoX.ChengL. (2010). Wnt1-cre-mediated conditional loss of Dicer results in malformation of the midbrain and cerebellum and failure of neural crest and dopaminergic differentiation in mice.J. Mol. Cell Biol.2152–163. 10.1093/jmcb/mjq008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  HurleyJ. H. (2010). The ESCRT complexes.Crit. Rev. Biochem. Mol. Biol.45463–487. 10.3109/10409238.2010.502516

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  IraciN.LeonardiT.GesslerF.VegaB.PluchinoS. (2016). Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles.Int. J. Mol. Sci.17:171. 10.3390/ijms17020171

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  JahnR.FasshauerD. (2012). Molecular machines governing exocytosis of synaptic vesicles.Nature490201–207. 10.1038/nature11320

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  JohnsonG. V.StoothoffW. H. (2004). Tau phosphorylation in neuronal cell function and dysfunction.J. Cell Sci.1175721–5729. 10.1242/jcs.01558

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  JohnsonR.ZuccatoC.BelyaevN. D.GuestD. J.CattaneoE.BuckleyN. J. (2008). A microRNA-based gene dysregulation pathway in Huntington’s disease.Neurobiol. Dis.29438–445. 10.1016/j.nbd.2007.11.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  JohnstoneR. M.AdamM.HammondJ. R.OrrL.TurbideC. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).J. Biol. Chem.2629412–9420.

  • Pubmed Abstract
  • Google Scholar

• 83

  KajimotoT.MohamedN.BadawyS.MatoveloS. A.HiraseM.NakamuraS.et al (2018). Involvement of Gbetagamma subunits of Gi protein coupled with S1P receptor on multivesicular endosomes in F-actin formation and cargo sorting into exosomes.J. Biol. Chem.293245–253. 10.1074/jbc.M117.808733

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  KalluriR.LeBleuV. S. (2020). The biology, function, and biomedical applications of exosomes.Science367:eaau6977. 10.1126/science.aau6977

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  KapiteinL. C.HoogenraadC. C. (2015). Building the Neuronal Microtubule Cytoskeleton.Neuron87492–506. 10.1016/j.neuron.2015.05.046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  KapogiannisD.BoxerA.SchwartzJ. B.AbnerE. L.BiragynA.MasharaniU.et al (2015). Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease.FASEB J.29589–596. 10.1096/fj.14-262048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  KatsudaT.OkiK.OchiyaT. (2015). Potential application of extracellular vesicles of human adipose tissue-derived mesenchymal stem cells in Alzheimer’s disease therapeutics.Methods Mol. Biol.1212171–181. 10.1007/7651_2014_98

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  Kawase KogaY.OtaegiG.SunT. (2009). Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system.Dev. Dyn.2382800–2812. 10.1002/dvdy.22109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  KellettK. A.HooperN. M. (2009). Prion protein and Alzheimer disease.Prion3190–194. 10.4161/pri.3.4.9980

  • CrossRef
  • Google Scholar

• 90

  KimA. H.ReimersM.MaherB.WilliamsonV.McMichaelO.McClayJ. L.et al (2010). MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders.Schizophr. Res.124183–191. 10.1016/j.schres.2010.07.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  KimB.Figueroa-RomeroC.PacutC.BackusC.FeldmanE. L. (2015). Insulin resistance prevents AMPK-induced Tau dephosphorylation through Akt-mediated Increase in AMPKSer-485 phosphorylation.J. Biol. Chem.29019146–19157. 10.1074/jbc.M115.636852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  KimD.NishidaH.AnS. Y.ShettyA. K.BartoshT. J.ProckopD. J. (2016). Chromatographically isolated CD63+ CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI.Proc. Natl. Acad. Sci. U.S.A.113170–175. 10.1073/pnas.1522297113

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  KingH. W.MichaelM. Z.GleadleJ. M. (2012). Hypoxic enhancement of exosome release by breast cancer cells.BMC Cancer12:421. 10.1186/1471-2407-12-421

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  KlumpermanJ.RaposoG. (2014). The complex ultrastructure of the endolysosomal system.Cold Spring Harb. Perspect. Biol.6:a016857. 10.1101/cshperspect.a016857

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  KoniuszS.AndrzejewskaA.MuracaM.SrivastavaA. K.JanowskiM.LukomskaB. (2016). Extracellular vesicles in physiology, pathology, and therapy of the immune and central nervous system, with focus on extracellular vesicles derived from mesenchymal stem cells as therapeutic tools.Front. Cell. Neurosci.10:109. 10.3389/fncel.2016.00109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  KowalJ.ArrasG.ColomboM.JouveM.MorathJ. P.Primdal-BengtsonB.et al (2016). Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.Proc. Natl. Acad. Sci. U.S.A.113E968–E977. 10.1073/pnas.1521230113

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  Kramer-AlbersE. M.BretzN.TenzerS.WintersteinC.MobiusW.BergerH.et al (2007). Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: trophic support for axons?Proteomics Clin. Appl.11446–1461. 10.1002/prca.200700522

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  KuwanoN.KatoT. A.MitsuhashiM.Sato-KasaiM.ShimokawaN.HayakawaK.et al (2018). Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: an exploratory pilot case-control study.J. Affect. Disord.24088–98. 10.1016/j.jad.2018.07.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  LachenalG.Pernet-GallayK.ChivetM.HemmingF. J.BellyA.BodonG.et al (2011). Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity.Mol. Cell. Neurosci.46409–418. 10.1016/j.mcn.2010.11.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  LaiR. C.ChenT. S.LimS. K. (2011). Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease.Regen. Med.6481–492. 10.2217/rme.11.35

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  LauP.FrigerioC. S.De StrooperB. (2014). Variance in the identification of microRNAs deregulated in Alzheimer’s disease and possible role of lincRNAs in the pathology: the need of larger datasets.Ageing Res. Rev.1743–53. 10.1016/j.arr.2014.02.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  LaulagnierK.JavaletC.HemmingF. J.ChivetM.LachenalG.BlotB.et al (2018). Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons.Cell. Mol. Life Sci.75757–773. 10.1007/s00018-017-2664-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  LeeB. R.KimJ. H.ChoiE. S.ChoJ. H.KimE. (2018). Effect of young exosomes injected in aged mice.Int. J. Nanomed.135335–5345. 10.2147/IJN.S170680

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  LeeS.MankhongS.KangJ. H. (2019). Extracellular vesicle as a source of Alzheimer’s biomarkers: opportunities and challenges.Int. J. Mol. Sci.20:E1728. 10.3390/ijms20071728

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  LeeY.ElA. S.WoodM. J. (2012). Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy.Hum. Mol. Genet.21R125–R134. 10.1093/hmg/dds317

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  LehmannB. D.PaineM. S.BrooksA. M.McCubreyJ. A.RenegarR. H.WangR.et al (2008). Senescence-associated exosome release from human prostate cancer cells.Cancer Res.687864–7871. 10.1158/0008-5472.CAN-07-6538

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  LiP.KaslanM.LeeS. H.YaoJ.GaoZ. (2017). Progress in exosome isolation techniques.Theranostics7789–804. 10.7150/thno.18133

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  LiuW.BaiX.ZhangA.HuangJ.XuS.ZhangJ. (2019). Role of exosomes in central nervous system diseases.Front. Mol. Neurosci.12:240. 10.3389/fnmol.2019.00240

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  LongQ.UpadhyaD.HattiangadyB.KimD.AnS. Y.ShuaiB.et al (2017). Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus.Proc. Natl. Acad. Sci. U.S.A.114E3536–E3545. 10.1073/pnas.1703920114

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  LotvallJ.HillA. F.HochbergF.BuzasE. I.Di VizioD.GardinerC.et al (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles.J. Extracell Vesicles3:26913. 10.3402/jev.v3.26913

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  LuarteA.HenziR.FernándezA.GaeteD.CisternasP.PizarroM.et al (2020). Astrocyte-derived small extracellular vesicles regulate dendritic complexity through miR-26a-5p Activity.Cells9:930. 10.3390/cells9040930

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  LuceyB. P.McCulloughA.LandsnessE. C.ToedebuschC. D.McLelandJ. S.ZazaA. M.et al (2019). Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease.Sci. Transl. Med.11:eaau6550. 10.1126/scitranslmed.aau6550

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  LukiwW. J.AlexandrovP. N.ZhaoY.HillJ. M.BhattacharjeeS. (2012). Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA.Neuroreport23621–626. 10.1097/WNR.0b013e32835542b0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  MallaR. R.PandrangiS.KumariS.GavaraM. M.BadanaA. K. (2018). Exosomal tetraspanins as regulators of cancer progression and metastasis and novel diagnostic markers.Asia Pac. J. Clin. Oncol.14383–391. 10.1111/ajco.12869

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  MartinL.LatypovaX.TerroF. (2011). Post-translational modifications of tau protein: implications for Alzheimer’s disease.Neurochem. Int.58458–471. 10.1016/j.neuint.2010.12.023

  • CrossRef
  • Google Scholar

• 116

  MatsumotoJ.StewartT.ShengL.LiN.BullockK.SongN.et al (2017). Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease?Acta Neuropathol. Commun.5:71. 10.1186/s40478-017-0470-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  McKelveyK. J.PowellK. L.AshtonA. W.MorrisJ. M.McCrackenS. A. (2015). Exosomes: mechanisms of uptake.J. Circ. Biomark4:7. 10.5772/61186

  • CrossRef
  • Google Scholar

• 118

  MenY.YelickJ.JinS.TianY.ChiangM.HigashimoriH.et al (2019). Exosome reporter mice reveal the involvement of exosomes in mediating neuron to astroglia communication in the CNS.Nat. Commun.10:4136. 10.1038/s41467-019-11534-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  MirandaA. M.LasieckaZ. M.XuY.NeufeldJ.ShahriarS.SimoesS.et al (2018). Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures.Nat. Commun.9:291. 10.1038/s41467-017-02533-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  Momen-HeraviF.SahaB.KodysK.CatalanoD.SatishchandranA.SzaboG. (2015). Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis.J. Transl. Med.13:261. 10.1186/s12967-015-0623-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  MorelL.ReganM.HigashimoriH.NgS. K.EsauC.VidenskyS.et al (2013). Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1.J. Biol. Chem.2887105–7116. 10.1074/jbc.M112.410944

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  MorrisG. P.ClarkI. A.ZinnR.VisselB. (2013). Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research.Neurobiol. Learn. Mem.10540–53. 10.1016/j.nlm.2013.07.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  MulcahyL. A.PinkR. C.CarterD. R. (2014). Routes and mechanisms of extracellular vesicle uptake.J. Extracell Vesicles3:24641. 10.3402/jev.v3.24641

  • CrossRef
  • Google Scholar

• 124

  MullinsR. J.MustapicM.GoetzlE. J.KapogiannisD. (2017). Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease.Hum. Brain Mapp.381933–1940. 10.1002/hbm.23494

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  NgolabJ.TrinhI.RockensteinE.ManteM.FlorioJ.TrejoM.et al (2017). Brain-derived exosomes from dementia with Lewy bodies propagate alpha-synuclein pathology.Acta Neuropathol. Commun.5:46. 10.1186/s40478-017-0445-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  OpheldersD. R.WolfsT. G.JellemaR. K.ZwanenburgA.AndriessenP.DelhaasT.et al (2016). Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia.Stem Cell. Transl. Med.5754–763. 10.5966/sctm.2015-0197

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  Otero-OrtegaL.Gómez De FrutosM. C.Laso-GarcíaF.Rodríguez-FrutosB.Medina-GutiérrezE.LopezJ. A.et al (2018). Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage.J. Cereb. Blood Flow Metab.38767–779. 10.1177/0271678X17708917

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  PackerA. N.XingY.HarperS. Q.JonesL.DavidsonB. L. (2008). The bifunctional microRNA miR-9/miR-9^∗ regulates REST and CoREST and is downregulated in Huntington’s disease.J. Neurosci.2814341–14346. 10.1523/JNEUROSCI.2390-08.2008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  PanB. T.JohnstoneR. M. (1983). Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor.Cell33967–978. 10.1016/0092-8674(83)90040-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  Pascua-MaestroR.GonzálezE.LilloC.GanforninaM. D.Falcón-PérezJ. M.SanchezD. (2019). Extracellular vesicles secreted by astroglial cells transport Apolipoprotein D to neurons and mediate neuronal survival upon oxidative stress.Front. Cell. Neurosci.12:526. 10.3389/fncel.2018.00526

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  PatzS.TrattnigC.GrunbacherG.EbnerB.GullyC.NovakA.et al (2013). More than cell dust: microparticles isolated from cerebrospinal fluid of brain injured patients are messengers carrying mRNAs, miRNAs, and proteins.J. Neurotrauma301232–1242. 10.1089/neu.2012.2596

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  PeretsN.HertzS.LondonM.OffenD. (2018). Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice.Mol. Autism9:57. 10.1186/s13229-018-0240-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  PerezM.AvilaJ.HernandezF. (2019). Propagation of Tau via Extracellular Vesicles.Front. Neurosci.13:698. 10.3389/fnins.2019.00698

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134

  PerkinsD. O.JeffriesC. D.JarskogL. F.ThomsonJ. M.WoodsK.NewmanM. A.et al (2007). microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.Genome Biol.8:R27. 10.1186/gb-2007-8-2-r27

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  PolancoJ. C.SciclunaB. J.HillA. F.GotzJ. (2016). Extracellular vesicles isolated from the brains of rTg4510 mice seed Tau protein aggregation in a threshold-dependent manner.J. Biol. Chem.29112445–12466. 10.1074/jbc.M115.709485

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  PrusinerS. B. (1982). Novel proteinaceous infectious particles cause scrapie.Science216136–144. 10.1126/science.6801762

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  PuglielliL.EllisB. C.SaundersA. J.KovacsD. M. (2003). Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis.J. Biol. Chem.27819777–19783. 10.1074/jbc.M300466200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  Raffo-RomeroA.ArabT.Al-AmriI. S.Le Marrec-CroqF.Van CampC.LemaireQ.et al (2018). Medicinal leech CNS as a model for exosome studies in the crosstalk between microglia and neurons.Int. J. Mol. Sci.19:E4124. 10.3390/ijms19124124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  RajendranL.BaliJ.BarrM. M.CourtF. A.Kramer-AlbersE. M.PicouF.et al (2014). Emerging roles of extracellular vesicles in the nervous system.J. Neurosci.3415482–15489. 10.1523/JNEUROSCI.3258-14.2014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  RajendranL.HonshoM.ZahnT. R.KellerP.GeigerK. D.VerkadeP.et al (2006). Alzheimer’s disease beta-amyloid peptides are released in association with exosomes.Proc. Natl. Acad. Sci. U.S.A.10311172–11177. 10.1073/pnas.0603838103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  RakJ.GuhaA. (2012). Extracellular vesicles–vehicles that spread cancer genes.Bioessays34489–497. 10.1002/bies.201100169

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  RatajczakJ.MiekusK.KuciaM.ZhangJ.RecaR.DvorakP.et al (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery.Leukemia20847–856. 10.1038/sj.leu.2404132

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  SaeediS.IsraelS.NagyC.TureckiG. (2019). The emerging role of exosomes in mental disorders.Transl. Psychiatry9:122. 10.1038/s41398-019-0459-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  SamanS.KimW.RayaM.VisnickY.MiroS.SamanS.et al (2012). Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.J. Biol. Chem.2873842–3849. 10.1074/jbc.M111.277061

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  SamanS.LeeN. C.InoyoI.JinJ.LiZ.DoyleT.et al (2014). Proteins recruited to exosomes by tau overexpression implicate novel cellular mechanisms linking tau secretion with Alzheimer’s disease.J. Alzheimers Dis.40S47–S70. 10.3233/JAD-132135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  Sanchez-CovarrubiasL.SloskyL. M.ThompsonB. J.DavisT. P.RonaldsonP. T. (2014). Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?Curr. Pharm. Des.201422–1449. 10.2174/13816128113199990463

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  Santa-MariaI.AlanizM. E.RenwickN.CelaC.FulgaT. A.Van VactorD.et al (2015). Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau.J. Clin. Invest.125681–686. 10.1172/JCI78421

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  SardarS. M.Ansell-SchultzA.CivitelliL.HildesjoC.LarssonM.LannfeltL.et al (2018). Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers.Acta Neuropathol.13641–56.

  • Pubmed Abstract
  • Google Scholar

• 149

  SarkarS.JunS.RellickS.QuintanaD. D.CavendishJ. Z.SimpkinsJ. W. (2016). Expression of microRNA-34a in Alzheimer’s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity.Brain Res.1646139–151. 10.1016/j.brainres.2016.05.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  SawamuraN.KoM.YuW.ZouK.HanadaK.SuzukiT.et al (2004). Modulation of amyloid precursor protein cleavage by cellular sphingolipids.J. Biol. Chem.27911984–11991. 10.1074/jbc.M309832200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  SaxtonR. A.SabatiniD. M. (2017). mTOR signaling in growth, metabolism, and disease.Cell169361–371. 10.1016/j.cell.2017.03.035

  • CrossRef
  • Google Scholar

• 152

  SempereL. F.FreemantleS.Pitha-RoweI.MossE.DmitrovskyE.AmbrosV. (2004). Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation.Genome Biol.5:R13. 10.1186/gb-2004-5-3-r13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153

  SethiP.LukiwW. J. (2009). Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex.Neurosci. Lett.459100–104. 10.1016/j.neulet.2009.04.052

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  SharmaP.SchiapparelliL.ClineH. T. (2013). Exosomes function in cell-cell communication during brain circuit development.Curr. Opin. Neurobiol.23997–1004. 10.1016/j.conb.2013.08.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  SharplesR. A.VellaL. J.NisbetR. M.NaylorR.PerezK.BarnhamK. J.et al (2008). Inhibition of γ-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes.FASEB J.221469–1478. 10.1096/fj.07-9357com

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  SheinermanK. S.TsivinskyV. G.CrawfordF.MullanM. J.AbdullahL.UmanskyS. R. (2012). Plasma microRNA biomarkers for detection of mild cognitive impairment.Aging (Albany NY)4590–605. 10.18632/aging.100486

  • CrossRef
  • Google Scholar

• 157

  SinhaM. S.Ansell-SchultzA.CivitelliL.HildesjöC.LarssonM.LannfeltL.et al (2018). Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers.Acta Neuropathol.13641–56. 10.1007/s00401-018-1868-1

  • CrossRef
  • Google Scholar

• 158

  SkogJ.WurdingerT.van RijnS.MeijerD. H.GaincheL.Sena-EstevesM.et al (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.Nat. Cell Biol.101470–1476. 10.1038/ncb1800

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  SongZ.ZhaoD.YangL. (2013). Molecular mechanisms of neurodegeneration mediated by dysfunctional subcellular organelles in transmissible spongiform encephalopathies.Acta Biochim. Biophys. Sin. (Shanghai)45452–464. 10.1093/abbs/gmt014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  SotiropoulosI.GalasM. C.SilvaJ. M.SkoulakisE.WegmannS.MainaM. B.et al (2017). Atypical, non-standard functions of the microtubule associated Tau protein.Acta Neuropathol. Commun.5:91. 10.1186/s40478-017-0489-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  StuffersS.SemW. C.StenmarkH.BrechA. (2009). Multivesicular endosome biogenesis in the absence of ESCRTs.Traffic10925–937. 10.1111/j.1600-0854.2009.00920.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  SunB.DalviP.AbadjianL.TangN.PulliamL. (2017). Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV.AIDS31F9–F17. 10.1097/QAD.0000000000001595

  • CrossRef
  • Google Scholar

• 163

  TakedaS. (2019). Progression of Alzheimer’s disease, tau propagation, and its modifiable risk factors.Neurosci. Res.14136–42. 10.1016/j.neures.2018.08.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  ThompsonA. G.GrayE.Heman-AckahS. M.MagerI.TalbotK.AndaloussiS. E.et al (2016). Extracellular vesicles in neurodegenerative disease – pathogenesis to biomarkers.Nat. Rev. Neurol.12346–357. 10.1038/nrneurol.2016.68

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  TimmersL.LimS. K.HoeferI. E.ArslanF.LaiR. C.van OorschotA. A.et al (2011). Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction.Stem Cell Res.6206–214. 10.1016/j.scr.2011.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  TrajkovicK.HsuC.ChiantiaS.RajendranL.WenzelD.WielandF.et al (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes.Science3191244–1247. 10.1126/science.1153124

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  TranP.XiangD.TranT.YinW.ZhangY.KongL.et al (2019). Exosomes and nanoengineering: a match made for precision therapeutics.Adv. Mater.18:e1904040. 10.1002/adma.201904040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  TrottaT.PanaroM. A.CianciulliA.MoriG.Di BenedettoA.PorroC. (2018). Microglia-derived extracellular vesicles in Alzheimer’s Disease: a double-edged sword.Biochem. Pharmacol.148184–192. 10.1016/j.bcp.2017.12.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  UrbanelliL.MaginiA.BurattaS.BrozziA.SaginiK.PolchiA.et al (2013). Signaling pathways in exosomes biogenesis, secretion and fate.Genes (Basel)4152–170. 10.3390/genes4020152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  ValadiH.EkstromK.BossiosA.SjostrandM.LeeJ. J.LotvallJ. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat. Cell Biol.9654–659. 10.1038/ncb1596

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  van der PolE.BoingA. N.HarrisonP.SturkA.NieuwlandR. (2012). Classification, functions, and clinical relevance of extracellular vesicles.Pharmacol. Rev.64676–705. 10.1124/pr.112.005983

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  Van GiauV.AnS. S. (2016). Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer’s disease.J. Neurol. Sci.360141–152. 10.1016/j.jns.2015.12.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  van NielG.CharrinS.SimoesS.RomaoM.RochinL.SaftigP.et al (2011). The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis.Dev. Cell21708–721. 10.1016/j.devcel.2011.08.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  van NielG.D’AngeloG.RaposoG. (2018). Shedding light on the cell biology of extracellular vesicles.Nat. Rev. Mol. Cell Biol.19213–228. 10.1038/nrm.2017.125

  • CrossRef
  • Google Scholar

• 175

  van NielG.Porto-CarreiroI.SimoesS.RaposoG. (2006). Exosomes: a common pathway for a specialized function.J. Biochem.14013–21. 10.1093/jb/mvj128

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  VillemagneV. L.BurnhamS.BourgeatP.BrownB.EllisK. A.SalvadoO.et al (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study.Lancet Neurol.12357–367. 10.1016/S1474-4422(13)70044-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  WangG.DinkinsM.HeQ.ZhuG.PoirierC.CampbellA.et al (2012). Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4) potential mechanism of apoptosis induction in Alzheimer disease (AD).J. Biol. Chem.28721384–21395. 10.1074/jbc.M112.340513

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  WangY.BalajiV.KaniyappanS.KrugerL.IrsenS.TepperK.et al (2017). The release and trans-synaptic transmission of Tau via exosomes.Mol. Neurodegener.12:5. 10.1186/s13024-016-0143-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  WatsonL. S.HamlettE. D.StoneT. D.Sims-RobinsonC. (2019). Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease.Mol. Neurodegener.14:22. 10.1186/s13024-019-0317-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  WattA. D.PerezK. A.FauxN. G.PikeK. E.RoweC. C.BourgeatP.et al (2011). Increasing the predictive accuracy of amyloid-beta blood-borne biomarkers in Alzheimer’s disease.J. Alzheimers Dis.2447–59. 10.3233/JAD-2010-101722

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  WebbR. L.KaiserE. E.JurgielewiczB. J.SpellicyS.ScovilleS. L.ThompsonT. A.et al (2018a). Human neural stem cell extracellular vesicles improve recovery in a porcine model of ischemic stroke.Stroke491248–1256. 10.1161/STROKEAHA.117.020353

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  WebbR. L.KaiserE. E.ScovilleS. L.ThompsonT. A.FatimaS.PandyaC.et al (2018b). Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model.Transl. Stroke Res.9530–539. 10.1007/s12975-017-0599-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  WeberJ. A.BaxterD. H.ZhangS.HuangD. Y.HuangK. H.LeeM. J.et al (2010). The microRNA spectrum in 12 body fluids.Clin. Chem.561733–1741. 10.1373/clinchem.2010.147405

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  WilliamsA. M.DennahyI. S.BhattiU. F.HalaweishI.XiongY.ChangP.et al (2019). Mesenchymal stem cell-derived exosomes provide neuroprotection and improve long-term neurologic outcomes in a swine model of traumatic brain injury and hemorrhagic shock.J. Neurotraum.3654–60. 10.1089/neu.2018.5711

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  WinstonC. N.AulstonB.RockensteinE. M.AdameA.PrikhodkoO.DaveK. N.et al (2019). Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo.J. Alzheimers Dis.67541–553. 10.3233/JAD-180776

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  WinstonC. N.GoetzlE. J.AkersJ. C.CarterB. S.RockensteinE. M.GalaskoD.et al (2016). Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.Alzheimers Dement.363–72. 10.1016/j.dadm.2016.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  WongH. K.VeremeykoT.PatelN.LemereC. A.WalshD. M.EsauC.et al (2013). De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease.Hum. Mol. Genet.223077–3092. 10.1093/hmg/ddt164

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  XiaoT.ZhangW.JiaoB.PanC.LiuX.ShenL. (2017). The role of exosomes in the pathogenesis of Alzheimer’disease.Transl. Neurodegener.6:3. 10.1186/s40035-017-0072-x

  • CrossRef
  • Google Scholar

• 189

  XiaoX.YuS.LiS.WuJ.MaR.CaoH.et al (2014). Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin.PLoS One9:e89534. 10.1371/journal.pone.0089534

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  XinH.KatakowskiM.WangF.QianJ.LiuX. S.AliM. M.et al (2017). MicroRNA-17–92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats.Stroke48747–753. 10.1161/STROKEAHA.116.015204

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  XinH.LiY.CuiY.YangJ. J.ZhangZ. G.ChoppM. (2013a). Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats.J. Cereb. Blood Flow Metab.331711–1715. 10.1038/jcbfm.2013.152

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  XinH.LiY.LiuZ.WangX.ShangX.CuiY.et al (2013b). MiR−133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome−enriched extracellular particles.Stem Cells312737–2746. 10.1002/stem.1409

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  YamadaK.CirritoJ. R.StewartF. R.JiangH.FinnM. B.HolmesB. B.et al (2011). In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.J. Neurosci.3113110–13117. 10.1523/JNEUROSCI.2569-11.2011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  YangJ.ZhangX.ChenX.WangL.YangG. (2017). Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia.Mol. Ther. Nucleic Acids7278–287. 10.1016/j.omtn.2017.04.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  YokoiA.Villar-PradosA.OliphintP. A.ZhangJ.SongX.De HoffP.et al (2019). Mechanisms of nuclear content loading to exosomes.Sci. Adv.5:eaax8849. 10.1126/sciadv.aax8849

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  YouY.IkezuT. (2019). Emerging roles of extracellular vesicles in neurodegenerative disorders.Neurobiol. Dis.130:104512. 10.1016/j.nbd.2019.104512

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  YuL. L.ZhuJ.LiuJ. X.JiangF.NiW. K.QuL. S.et al (2018). A comparison of traditional and novel methods for the separation of exosomes from human samples.Biomed. Res. Int.2018:3634563. 10.1155/2018/3634563

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  YuyamaK.IgarashiY. (2017). Exosomes as carriers of Alzheimer’s amyloid-ss.Front. Neurosci.11:229. 10.3389/fnins.2017.00229

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  YuyamaK.SunH.MitsutakeS.IgarashiY. (2012). Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia.J. Biol. Chem.28710977–10989. 10.1074/jbc.M111.324616

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  YuyamaK.SunH.SakaiS.MitsutakeS.OkadaM.TaharaH.et al (2014). Decreased amyloid-β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice.J. Biol. Chem.28924488–24498. 10.1074/jbc.M114.577213

  • CrossRef
  • Google Scholar

• 201

  YuyamaK.SunH.UsukiS.SakaiS.HanamatsuH.MiokaT.et al (2015). A potential function for neuronal exosomes: sequestering intracerebral amyloid−β peptide.FEBS Lett.58984–88. 10.1016/j.febslet.2014.11.027

  • CrossRef
  • Google Scholar

• 202

  ZhangY.ChoppM.ZhangZ. G.KatakowskiM.XinH.QuC.et al (2017). Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2D and 3D conditions improves functional recovery in rats after traumatic brain injury.Neurochem. Int.11169–81. 10.1016/j.neuint.2016.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  ZhengT.PuJ.ChenY.MaoY.GuoZ.PanH.et al (2017). Plasma exosomes spread and cluster around β-amyloid plaques in an animal model of Alzheimer’s disease.Front. Aging Neurosci.9:12. 10.3389/fnagi.2017.00012

  • CrossRef
  • Google Scholar

• 204

  ZhuQ.HeonM.ZhaoZ.HeM. (2018). Microfluidic engineering of exosomes: editing cellular messages for precision therapeutics.Lab. Chip.181690–1703. 10.1039/c8lc00246k

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  ZhuangX.XiangX.GrizzleW.SunD.ZhangS.AxtellR. C.et al (2011). Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.Mol. Ther.191769–1779. 10.1038/mt.2011.164

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  ZitvogelL.RegnaultA.LozierA.WolfersJ.FlamentC.TenzaD.et al (1998). Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.Nat. Med.4594–600. 10.1038/nm0598-594

  • Pubmed Abstract
  • CrossRef
  • Google Scholar